Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales Inch Up 1.1% in June: Crecon
August 12, 2022
- AbbVie Seeks Crohn’s Disease Nod for Rinvoq in Japan
August 12, 2022
- Shionogi’s COVID Pill Shows In Vitro Antiviral Activity Against BA.2.75
August 12, 2022
- PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics
August 12, 2022
- Eisai, Lifenet Insurance Enter Capital, Biz Tie-Up to Build Dementia Ecosystem
August 12, 2022
- Opdivo Tops Japan Drug Sales Ranking 7 Months Running: Encise July Data
August 12, 2022
- Moderna Files Omicron Bivalent Vaccine in Japan
August 10, 2022
- Sumitomo Drops 100 Billion Yen Diabetes Sales Goal as Trulicity Collab Ends
August 10, 2022
- Nipro Eyes 60% AG Share in Nexium Generic Market: Exec
August 10, 2022
- Daiichi Sankyo’s HER3 ADC Enters PIII for EGFR-Mutated NSCLC
August 10, 2022
- Yen’s Fall Reaps 10 Billion Yen-Plus Gain on Sales for 5 Japan Makers, Takeda Gets 8.8 Billion Yen: April-June
August 9, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
- Myfembree Snags Endometriosis Nod in US: Myovant/Pfizer
August 9, 2022
- Maruho’s Mitchga Now Available for Eczema Itching in Japan
August 9, 2022
- Chugai Settles Patent Suit against Fresenius Kabi over Alecensa
August 9, 2022
- Enhertu Grabs US Approval for HER2 Low Breast Cancer: Daiichi Sankyo/AZ
August 9, 2022
- Incyte Files Pemazyre for Myelogenous/Lymphatic Tumor in Japan
August 9, 2022
- Sales Rep’s Online Meetings Fall 8.4% YOY in June: Intage
August 9, 2022
- Single-Wholesaler Distribution Unlikely to Constitute Antimonopoly Law Violation: Expert
August 8, 2022
- Kyowa Kirin Chief Sees Late-Stage Assets as Next Japan Biz Drivers, Room for Growth for Duvroq/Crysvita
August 8, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…